The 18mos. results from an ongoing 2yr. P-II study (LBS-008-CT02) evaluating Tinlarebant in adolescent patients with STGD1
The results from fundus autofluorescence (FAF) imaging showed that ~60% of patients demonstrated no incident atrophic retinal lesions, mean visual acuity was stabilized in the study cohort, 9 out of 12 patients experienced mild xanthopsia/chromatopsia and delayed dark adaptation & 1 out of 12 patients experienced night vision impairment
The therapy was safe & well tolerated, no clinical changes in retinal thickness were seen @18mos. The company is currently enrolling patients in a 2yr. P-III study (DRAGON) of Tinlarebant for STGD1 & plans to begin enrolling patients in a 2yr. P-III study (PHOENIX) for GA in mid-2023
Ref: Globenewswire | Image: Belite Bio
